Industry News

Biotechnology Industry News

Following a string of clinical…

August 6th, 2026|FierceBiotech|

Following a string of clinical setbacks, Vistagen’s nasal spray for social anxiety has now failed to top placebo even when given as a double dose. But just like with prior disappointing readouts, the biotech has

Tarsus Pharmaceuticals is fronting…

August 6th, 2026|FierceBiotech|

Tarsus Pharmaceuticals is fronting $450 million to acquire Alkeus Pharmaceuticals for its phase 3-stage retinal disease therapy that's being touted as a potential blockbuster.

BioVie has hailed phase 2 data as…

August 6th, 2026|FierceBiotech|

BioVie has hailed phase 2 data as evidence that bezisterim could represent a “meaningful advance” in the treatment of Parkinson’s disease. But the biotech focused on a new composite measure, rather than its stated primary

Context Therapeutics has stopped…

August 6th, 2026|FierceBiotech|

Context Therapeutics has stopped development of the bispecific T-cell engager CT-95, freeing up cash to extend its runway beyond readouts on its two priority clinical programs.

Actimed Therapeutics has brought…

August 6th, 2026|FierceBiotech|

Actimed Therapeutics has brought the full rights to its wasting disease drug back in house, securing “strategic control” over the asset but losing out on a shot at over $120 million in biobucks.

A little over a year ago, LifeMine…

August 5th, 2026|FierceBiotech|

A little over a year ago, LifeMine Therapeutics laid off staff and put its fungus-based platform on ice to focus its dwindling resources on its lead asset. Now, the Massachusetts biotech is shaking off the

Novo Nordisk CFO Karsten Munk…

August 5th, 2026|FierceBiotech|

Novo Nordisk CFO Karsten Munk Knudsen spoke to Fierce the morning the company unveiled its second-quarter earnings, reflecting on Novo’s “roller coaster” financial journey, the pressure of navigating its shifting fortunes and why he remains

Eli Lilly has axed another trial…

August 5th, 2026|FierceBiotech|

Eli Lilly has axed another trial of a gene therapy acquired in its $1 billion Prevail Therapeutics buyout, further denting the drugmaker’s chances of delivering a return on its investment.

Novo Nordisk’s CEO admitted the…

August 5th, 2026|FierceBiotech|

Novo Nordisk’s CEO admitted the Danish pharma has had “a couple of setbacks” in the wake of mixed data for CagriSema and its cardiovascular hopeful ziltivekimab, while stressing that the company is already on the

Attovia Therapeutics has accreted…

August 5th, 2026|FierceBiotech|

Attovia Therapeutics has accreted a hefty $289 million from its IPO to power its anti-itch drugs through clinical development, marking another upsized listing in what has become a banner year for biotech Nasdaq debuts.

Amgen has ended development of its…

August 4th, 2026|FierceBiotech|

Amgen has ended development of its early-stage obesity drug AMG 513, foisting its hopes for a slice of the massive weight loss market onto the shoulders of phase 3 candidate MariTide.

Expedition Therapeutics has…

August 4th, 2026|FierceBiotech|

Expedition Therapeutics has secured an oversubscribed $115 million series B financing from a line-up of big-name investors to propel its lead DPP1 inhibitor through phase 2.

Lisata is laying off 72% of its…

August 4th, 2026|FierceBiotech|

Lisata is laying off 72% of its workforce, including its chief medical officer, as the solid tumor biotech tries to navigate a new future after a planned merger with cancer imaging company Kuva Labs fell

Pfizer has axed two clinical-stage…

August 4th, 2026|FierceBiotech|

Pfizer has axed two clinical-stage obesity programs, dropping a GLP-1 receptor agonist from the Metsera buyout and a GIPR antagonist as part of its quarterly pipeline cleanout.

A phase 2 trial of Merck &…

August 4th, 2026|FierceBiotech|

A phase 2 trial of Merck & Co.’s anti-TL1A monoclonal antibody has missed its primary endpoint, closing off one avenue for expansion of an asset acquired in a $10.8 billion takeover. The setback was offset

Pathos AI has agreed to pay $125…

August 4th, 2026|FierceBiotech|

Pathos AI has agreed to pay $125 million for a bispecific antibody-drug conjugate from China’s Alphamab Oncology, while adding a Big Pharma partner in the form of AstraZeneca.